Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …

Abstract Background KRAS G12C is a mutation that occurs in approximately 3 to 4% of
patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has …

Abstract Background Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was
designed to have high potency and selectivity. Methods In a phase 1 study, we evaluated …

PURPOSE Adagrasib, a KRASG12C inhibitor, has demonstrated clinical activity in patients
with KRAS G12C-mutated non–small-cell lung cancer (NSCLC) and colorectal cancer …

There is a continuing debate about the proportion of cancer patients that benefit from
precision oncology, attributable in part to conflicting views as to which molecular alterations …

Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Abstract KRAS G12C mutation is prevalent in~ 4% of colorectal cancer (CRC) and is
associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest …

The current third-line (and beyond) treatment options for RAS-mutant metastatic colorectal
cancer have yielded limited efficacy. At the time of study start, the combination of sotorasib, a …

Adagrasib (KRAZATI™) is an orally available, potent, irreversible, small molecule inhibitor of
KRAS G12C mutant isoform being developed by Mirati Therapeutics for the treatment of …